CREEKWOOD PHARMS
GenericsCREEKWOOD PHARMS is a generic drug manufacturer focused on Neurology, Cardiovascular, Infectious Disease.
CREEKWOOD PHARMS's Key Drugs
CREEKWOOD PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CREEKWOOD PHARMS's Recent FDA Approvals
New NDA/BLA approvals for CREEKWOOD PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
CREEKWOOD PHARMS's Therapeutic Areas
CREEKWOOD PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CREEKWOOD PHARMS's Top Competitors
CREEKWOOD PHARMS's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CREEKWOOD PHARMS Pipeline Snapshot
Active clinical trials for CREEKWOOD PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1996-01-27
- Latest
- 2026-08-14
- Applications
- 9